Table: marine pharmacognosy
Question: Are compounds in phase II clinical trials more likely to target cognition or schizophrenia compared to compounds in other phases? Answer with only 'Yes' or 'No' that is most accurate and nothing else.
Step 1 (Operation, Grouping): clinical status
Step 2 (Operation, Indexing): disease area
Step 3 (Reasoning, Aggregating): COUNT, disease area equals to congnition , schizophrenia
Step 4 (Reasoning, Arithmetic): comparison, phase II and others
Answer: Yes